SOPHiA GENETICS Earnings Call: Growth With Caveats

Sophia Genetics Sa ((SOPH)) has held its Q1 earnings call. Read on for the main highlights of the call.

SOPHiA GENETICS’ latest earnings call struck a cautiously upbeat tone, with strong revenue and volume growth underscoring improving fundamentals even as costs, currency swings, and legal bills weighed on the bottom line. Management painted a picture of a scalable platform gaining commercial traction and edging toward profitability, but investors will need to watch execution in the second half.

Strong Revenue Growth

SOPHiA GENETICS reported Q1 2026 revenue of $21.7 million, up 22% from $17.8 million a year earlier, outpacing many diagnostics peers and confirming resilient demand across its platform. Management reaffirmed its full‑year 2026 revenue outlook of $92–94 million, implying 20–22% growth and signaling confidence despite macro and FX headwinds.

Record and Growing Analysis Volume

Platform usage continued to scale, with about 108,000 analyses processed in Q1, a 16% year‑on‑year increase that highlights robust platform adoption and clinical engagement. March set a company record with more than 40,000 patients analyzed, pushing SOPHiA’s cumulative genomic profiles to 2.5 million since inception and reinforcing its data‑driven competitive edge.

High Margins and Profitability Progress

Adjusted gross margin remained strong at 75.4% in Q1, only slightly below last year’s 75.7%, translating into adjusted gross profit of $16.4 million, up 22% year‑over‑year and in line with revenue growth. The company reiterated its 2026 adjusted EBITDA loss guidance of $29–32 million, an improvement from 2025’s $41.5 million loss, and expects modest margin expansion as scale benefits build.

Customer Base and Retention Strength

The core genomic customer base expanded to 537 accounts from 490 a year ago, reflecting steady new wins and reinforcing SOPHiA’s platform relevance in clinical genomics. Annualized revenue churn remained below 1% and net dollar retention improved to 117% from 103%, signaling strong same‑customer expansion and a durable recurring revenue foundation.

Regional and Application Momentum

Geographically, U.S. volumes climbed 28% and APAC volumes rose 31% year‑over‑year, while EMEA revenue grew about 30%, outpacing the company‑wide average and becoming an important growth engine. By application, hematology/oncology revenue increased 24% and rare/inherited disease volumes grew more than 20%, helped by the ramp of enhanced exome testing and broader clinical use cases.

Liquid Biopsy and New Applications

Liquid biopsy adoption accelerated with roughly 3,000 analyses in Q1, more than doubling from the prior year and confirming demand for less‑invasive cancer testing options. The company has signed 100 customers for MSK Impact and MSK Access in under two years, and about half are implementing the PBM workflow, with associated revenue expected to begin flowing over the next 12 months.

Biopharma Momentum and Partnerships

Biopharma traction is building, with new and expanding collaborations that include major names such as AstraZeneca, Johnson & Johnson, and Kartos, alongside ongoing progress with Myriad. While still a small contributor, biopharma turned modestly positive in Q1 and management expects this segment to ramp meaningfully through 2027, adding a higher‑margin growth leg.

Capital and Liquidity Actions

SOPHiA ended Q1 with $65.4 million in cash and equivalents, a figure that includes $14.5 million raised via its at‑the‑market program and provides a buffer against near‑term volatility. The company also expanded its credit facility by $25 million in partnership with Perceptive Advisors, bolstering liquidity to fund growth investments and support an active legal defense.

Operational Efficiency and AI‑Driven Cost Actions

Management implemented targeted cost measures in Q1, trimming headcount and non‑labor spending, with emphasis on general and administrative functions and support operations to enhance operating leverage. Early internal deployment of productivity‑focused AI tools has delivered positive initial results, pointing to additional efficiency gains as these technologies are scaled across workflows.

Technology and Strategic Positioning

The company continues to highlight its cloud‑based analytics platform as both highly scalable and cost‑efficient, underpinned by a unique global data footprint spanning 75 countries that enriches its algorithms. Strategic priorities are centered on large next‑generation sequencing applications, minimal residual disease, multimodal analytics, and durable real‑world‑evidence and companion diagnostic offerings.

Operating Loss and Elevated Expenses

Despite revenue growth, the Q1 operating loss widened to $17.3 million from $16.0 million last year as total operating expenses climbed to $32.0 million from $28.2 million. Management pointed to currency translation effects and legal spending as key drivers of the increase, partially offsetting underlying efficiency gains and delaying the march to profitability.

Increased Cash Burn

Cash burn rose to $19.5 million in Q1 from $11.7 million a year earlier, reflecting higher annual bonus and commission payouts linked to prior‑year performance, lab build‑out spending of roughly $1 million, and litigation‑related payments. While management framed these as partly timing‑related and investment‑driven, sustained high burn remains a focal risk for equity holders.

Foreign Exchange Headwinds

The Swiss franc’s approximately 14% appreciation against the U.S. dollar over the past year materially lifted the dollar‑denominated cost base tied to Swiss payroll and facilities. This currency move weighed on reported operating results and, if sustained, could continue to pressure margins even as underlying unit economics and pricing trends remain favorable.

Ongoing Litigation and Legal Costs

The ongoing patent dispute with Guardant Health generated about $1.4 million in Q1 legal expenses, partially offset by interim cost recoveries ordered by the Unified Patent Court. Even after roughly $0.7 million in net impact this quarter, management emphasized that litigation remains a continuing cost and risk factor that could introduce volatility into future earnings.

GAAP Margin Slightly Down

GAAP gross margin slipped modestly to 68.0% in Q1 2026 from 68.7% a year earlier, mirroring the small decline in adjusted gross margin to 75.4% from 75.7% as mix and FX effects edged against the company. While the declines were minor, they highlight that even highly scalable software‑driven models can face intermittent margin pressure from external factors.

Softness in Latin America

Latin America remained a weak spot, with revenue down more than 30% year‑over‑year, prompting management to initiate leadership changes and remediation efforts in the region. Although LATAM is still a relatively small slice of total revenue, the company continues to view it as strategically important and aims to stabilize performance over time.

Back‑Half Weighted Growth and Execution Risk

Management cautioned that 2026 growth will be heavily back‑half weighted as new bookings signed in 2025 and early 2026 ramp into full‑run revenue. This puts a premium on smooth customer onboarding and implementation, and any delays in go‑lives or usage scaling could challenge the company’s ability to deliver on its full‑year targets.

Pharma Revenue Still Early and Lumpy

Although momentum in the pharma segment is clearly building and contributed modestly in Q1, the company is maintaining conservative near‑term modeling for this line of business. Management emphasized that biopharma revenue can be inherently lumpy and that the more substantial step‑up is expected from 2027 onward as current collaborations mature and scale.

Forward‑Looking Guidance and Outlook

Looking ahead, SOPHiA reiterated 2026 revenue guidance of $92–94 million and an adjusted EBITDA loss of $29–32 million, with expectations of modest gross‑margin improvement and approaching adjusted‑EBITDA breakeven by year‑end. The company anticipates ASP uplift as higher‑value tests and pharma projects ramp in the second half, backed by strong customer metrics, enhanced liquidity, and a clear path toward positive adjusted EBITDA in 2027.

SOPHiA GENETICS’ earnings call painted a story of strong demand, high‑margin growth, and expanding strategic partnerships, offset by rising costs, FX pressures, and legal overhang. For investors, the narrative is one of a differentiated platform steadily scaling toward profitability, but with execution in the back half of 2026 and disciplined cash management likely to determine how the stock trades from here.